Eluxadoline — Discount Pricing

Other medications in Digestive Health

• Golimumab
• Infliximab
• Lactulose Solution
• Linaclotide
• Lubiprostone
• Metoclopramide
• Misoprostol
• Natalizumab

About Eluxadoline

Eluxadoline is a prescription medication used to treat Irritable Bowel Syndrome with Diarrhea (IBS-D), a chronic condition affecting millions. Managing IBS-D can be challenging, both physically and financially. At TheDrugClub, we're dedicated to helping our members access essential medications like eluxadoline more affordably, ensuring relief is within reach.

Understanding Eluxadoline for IBS-D

Irritable Bowel Syndrome with Diarrhea (IBS-D) is a common gastrointestinal disorder characterized by recurrent abdominal pain, cramping, and frequent loose or watery stools. It can significantly impact daily life, making effective management crucial. Eluxadoline, often known by its brand name Viberzi, is a targeted prescription medication specifically approved for the treatment of IBS-D in adults.

How Eluxadoline Works

Eluxadoline operates through a unique mechanism of action within the digestive system. It is a mixed mu-opioid receptor agonist, delta-opioid receptor antagonist, and kappa-opioid receptor agonist. In simpler terms, it acts on specific opioid receptors in the gut, but unlike traditional opioids, it has minimal absorption into the bloodstream, reducing the risk of central nervous system side effects. By engaging these receptors, eluxadoline helps to reduce abdominal pain and discomfort, slow down exaggerated bowel contractions, and improve stool consistency, thereby alleviating the primary symptoms of IBS-D.

Typical Costs of Eluxadoline

As a brand-name prescription medication, eluxadoline can be quite expensive, often posing a significant financial burden for patients. Without insurance or discount programs, the typical retail cost for a 30-day supply can range

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Eluxadoline is approved for (FDA label)

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 16, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Eluxadoline (FDA label)

75 mg tablets: capsule-shaped tablets are coated in pale-yellow to light tan color debossed with “FX75” on one side. Each tablet contains 75 mg eluxadoline. 100 mg tablets: capsule-shaped tablets are coated in pink-orange to peach color debossed with “FX100” on one side. Each tablet contains 100 mg eluxadoline. Tablets: 75 mg and 100 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7821bd40-4c84-4984-951b-6436ae20421a. SPL document ID: 50b9e7bd-c577-4562-9d26-1d8dcb8cf2ef. Label effective date: July 16, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Eluxadoline (FDA label)

The following adverse reactions described below and elsewhere in the labeling include: Pancreatitis [see Warnings and Precautions ( 5.1 )] Sphincter of Oddi Spasm [ see Warnings and Precautions ( 5.2 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.3 )] Constipation [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (>5%) are constipation, nausea and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1- 800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial s Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7821bd40-4c84-4984-951b-6436ae20421a. SPL document ID: 50b9e7bd-c577-4562-9d26-1d8dcb8cf2ef. Label effective date: July 16, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.